Cancer drug marches toward filing

Share this article:

Merrimack Pharmaceuticals said today that its candidate for metastatic pancreatic cancer, MM-398, in combination with 5-FU and leucovorin, met its primary endpoint and will be submitted to the FDA in 2014. The agency granted MM-398 an orphan drug designation for metastatic pancreatic cancer in 2011.

MM-398+5-FU+leucovorin saw an overall survival of 6.1 months, representing a 1.9-month improvement over the 4.2 months of survival demonstrated by a control arm of 5-FU+leucovorin alone. MM-398, on its own, did not demonstrate a statistically significant survival advantage, though.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.